Jin‐Ji Yang

8.8k total citations · 2 hit papers
146 papers, 4.9k citations indexed

About

Jin‐Ji Yang is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Jin‐Ji Yang has authored 146 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 121 papers in Pulmonary and Respiratory Medicine, 102 papers in Oncology and 33 papers in Cancer Research. Recurrent topics in Jin‐Ji Yang's work include Lung Cancer Treatments and Mutations (117 papers), Lung Cancer Research Studies (46 papers) and Colorectal Cancer Treatments and Studies (32 papers). Jin‐Ji Yang is often cited by papers focused on Lung Cancer Treatments and Mutations (117 papers), Lung Cancer Research Studies (46 papers) and Colorectal Cancer Treatments and Studies (32 papers). Jin‐Ji Yang collaborates with scholars based in China, United States and United Kingdom. Jin‐Ji Yang's co-authors include Yi‐Long Wu, Xu‐Chao Zhang, Qing Zhou, Hong‐Hong Yan, Wen‐Zhao Zhong, Hai‐Yan Tu, Jian Su, Xue‐Ning Yang, Hua‐Jun Chen and Zhi Xie and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer Cell.

In The Last Decade

Jin‐Ji Yang

138 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

2016 741 citations Zhong‐Yi Dong, Wen‐Zhao Zhong et al. Clinical Cancer Research profile →
Using patient-derived organoids to predict locally advanced or metastatic lung cancer tumor response: A real-world study

2023 110 citations Hanmin Wang, Junwei Su et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jin‐Ji Yang China	36	3.9k	3.5k	1.2k	1.1k	306	146	4.9k
Hiroaki Akamatsu Japan	28	3.8k 1.0×	3.5k 1.0×	1.2k 1.0×	1.1k 1.0×	220 0.7×	144	5.1k
Manuel Cobo Spain	30	3.4k 0.9×	3.6k 1.1×	1.3k 1.1×	1.1k 1.0×	565 1.8×	219	5.3k
Tiziana Usari Italy	17	3.5k 0.9×	3.1k 0.9×	1.2k 1.0×	1.0k 1.0×	235 0.8×	51	4.4k
Willemijn S.M.E. Theelen Netherlands	16	3.3k 0.9×	3.0k 0.9×	998 0.8×	873 0.8×	385 1.3×	33	4.4k
Venice Archer United Kingdom	9	3.6k 0.9×	3.6k 1.0×	919 0.8×	663 0.6×	276 0.9×	16	4.6k
Hong‐Hong Yan China	31	2.8k 0.7×	2.5k 0.7×	870 0.7×	866 0.8×	223 0.7×	133	3.7k
Radj Gervais France	24	4.0k 1.0×	3.7k 1.1×	1.1k 0.9×	617 0.6×	162 0.5×	83	5.2k
Chong‐Rui Xu China	27	3.5k 0.9×	3.1k 0.9×	1.0k 0.9×	931 0.9×	202 0.7×	122	4.4k
Mircea Dediu Romania	19	5.1k 1.3×	4.8k 1.4×	1.6k 1.3×	894 0.8×	173 0.6×	55	6.6k
Mark S. Huberman United States	30	3.3k 0.8×	3.0k 0.9×	1.2k 1.0×	778 0.7×	154 0.5×	80	4.5k

Countries citing papers authored by Jin‐Ji Yang

Since Specialization

Citations

This map shows the geographic impact of Jin‐Ji Yang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jin‐Ji Yang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jin‐Ji Yang more than expected).

Fields of papers citing papers by Jin‐Ji Yang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jin‐Ji Yang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jin‐Ji Yang. The network helps show where Jin‐Ji Yang may publish in the future.

Co-authorship network of co-authors of Jin‐Ji Yang

This figure shows the co-authorship network connecting the top 25 collaborators of Jin‐Ji Yang. A scholar is included among the top collaborators of Jin‐Ji Yang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jin‐Ji Yang. Jin‐Ji Yang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Kuang, Jing, Jin‐Ji Yang, Haili Wang, et al.. (2025). APOC1 inhibit NKTCL doxorubicin sensitivity by promoting mitophagy. IUBMB Life. 77(1). e2942–e2942.

Deng, Jie, Hong‐Hong Yan, Ming‐Yu Yang, et al.. (2023). WS02.13 PD-L1 Expression Guidance on Sintilimab versus Pembrolizumab in Untreated Advanced NSCLC (CTONG1901). Journal of Thoracic Oncology. 18(11). S38–S39. 1 indexed citations

Liu, Si‐Yang Maggie, Jie Huang, Jia‐Yi Deng, et al.. (2023). PD-L1 expression guidance on sintilimab versus pembrolizumab with or without platinum-doublet chemotherapy in untreated patients with advanced non-small cell lung cancer (CTONG1901): A phase 2, randomized, controlled trial. Science Bulletin. 69(4). 535–543. 18 indexed citations

Huang, Jie, et al.. (2022). Genomic and Transcriptomic Analysis of Neuroendocrine Transformation in ALK-Rearranged Lung Adenocarcinoma After Treatments With Sequential ALK Inhibitors: A Brief Report. JTO Clinical and Research Reports. 3(6). 100338–100338. 9 indexed citations

Su, Junwei, Zhi Xie, Hanmin Wang, et al.. (2022). Clinical outcomes of EGFR+/METamp+ vs. EGFR+/METamp‐ untreated patients with advanced non‐small cell lung cancer. Thoracic Cancer. 13(11). 1619–1630. 11 indexed citations

Zheng, Mei-Mei, Hai‐Yan Tu, Jin‐Ji Yang, et al.. (2021). Clinical outcomes of non–small cell lung cancer patients with leptomeningeal metastases after immune checkpoint inhibitor treatments. European Journal of Cancer. 150. 23–30. 19 indexed citations

Chen, Yu, Zhi Xie, Jie Jiang, et al.. (2021). High SHP2 expression determines the efficacy of PD‐1/PD‐L1 inhibitors in advanced KRAS mutant non‐small cell lung cancer. Thoracic Cancer. 12(19). 2564–2573. 9 indexed citations

Zhou, Qing, Chong‐Rui Xu, Ying Cheng, et al.. (2021). Bevacizumab plus erlotinib in Chinese patients with untreated, EGFR-mutated, advanced NSCLC (ARTEMIS-CTONG1509): A multicenter phase 3 study. Cancer Cell. 39(9). 1279–1291.e3. 144 indexed citations

Wei, Xue‐Wu, Xin Gao, Xu‐Chao Zhang, et al.. (2020). Mutational landscape and characteristics of ERBB2 in non‐small cell lung cancer. Thoracic Cancer. 11(6). 1512–1521. 35 indexed citations

10.

Zheng, Mei-Mei, Yang-Si Li, Hai‐Yan Tu, et al.. (2020). Genotyping of Cerebrospinal Fluid Associated With Osimertinib Response and Resistance for Leptomeningeal Metastases in EGFR-Mutated NSCLC. Journal of Thoracic Oncology. 16(2). 250–258. 50 indexed citations

11.

Zheng, Mei-Mei, Yang-Si Li, Ben‐Yuan Jiang, et al.. (2019). Clinical Utility of Cerebrospinal Fluid Cell-Free DNA as Liquid Biopsy for Leptomeningeal Metastases in ALK-Rearranged NSCLC. Journal of Thoracic Oncology. 14(5). 924–932. 75 indexed citations

12.

Kang, Jin‐Hyoung, Hua‐Jun Chen, Xu‐Chao Zhang, et al.. (2018). Heterogeneous responses and resistant mechanisms to crizotinib in ALK‐positive advanced non‐small cell lung cancer. Thoracic Cancer. 9(9). 1093–1103. 17 indexed citations

13.

Huang, Shu‐Mei, Si-Pei Wu, Ri-Qiang Liao, et al.. (2017). P2.03b-043 Peripheral Blood CD45RA+ CCR7+ Naive T Cells Were Correlated with Prognosis in Non-Small Cell Lung Cancer Patients. Journal of Thoracic Oncology. 12(1). S961–S962. 1 indexed citations

14.

Zhang, Xu‐Chao, Zhen Wang, Jin‐Ji Yang, et al.. (2017). Establishment of a Novel Method for Screening Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance Mutations in Lung Cancer. Chinese Medical Journal. 130(12). 1446–1453. 1 indexed citations

15.

Zhong, Wen‐Zhao, Xue‐Ning Yang, Hong‐Hong Yan, et al.. (2017). P1.05-046 Randomized Study of Adjuvant Docetaxel vs. Observation for Completely Resected Stage IB-IIIa NSCLC with 11 Years' Median Follow-Up. Journal of Thoracic Oncology. 12(1). S642–S643. 1 indexed citations

16.

Dong, Song, Ning Zhao, Wei Deng, et al.. (2017). Supraclavicular lymph node incisional biopsies have no influence on the prognosis of advanced non-small cell lung cancer patients: a retrospective study. World Journal of Surgical Oncology. 15(1). 12–12. 2 indexed citations

17.

Dong, Zhong‐Yi, Wen‐Zhao Zhong, Xu‐Chao Zhang, et al.. (2016). Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma. Clinical Cancer Research. 23(12). 3012–3024. 741 indexed citations breakdown →

18.

Yang, Jin‐Ji, et al.. (2016). [Burden of disease attributed to high total cholesterol in 2013 in China].. PubMed. 50(9). 764–768. 1 indexed citations

19.

Soria, J.C., Soo Wan Kim, Yi‐Long Wu, et al.. (2016). Gefitinib/chemotherapy vs chemotherapy in EGFR mutation-positive NSCLC after progression on 1st line gefitinib (IMPRESS study): Final overall survival (OS) analysis. Annals of Oncology. 27. vi416–vi416. 13 indexed citations

20.

Zhang, Xu‐Chao, Li Zhang, Changli Wang, et al.. (2013). [Consensus on dignosis for ALK positive non-small cell lung cancer in China, the 2013 version].. PubMed. 42(6). 402–6. 22 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact